breast cancer - HR positive | ||
la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |
abemaciclib based treatment | ||
abemaciclib plus aromatase inhibitor | MONARCH 3 | |
abemaciclib plus endocrine therapy | MonarchE | |
abemaciclib plus fulvestrant | MONARCH 2 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -